Skip to content

ΕτικέταNovartis

A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year

Earlier this year, BIO and TEConomy Partners released their 2018 “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry” report. It was the eighth biennial report, and focused on the economic progress and the footprint … Continue Reading A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year

As Brexit Nears, Drug Companies are Stockpiling Medicines in Britain

Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs. Reuters notes, “At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than … Continue Reading As Brexit Nears, Drug Companies are Stockpiling Medicines in Britain

‘Long way to go’ before top pharma companies’ digital presence measures up to current tech standards: study

Medical expertise in the pharma industry? Check. Demonstrated digital know-how amongst the industry’s main players? Not quite yet. That was the windup of a study, released last month, that examined … Continue Reading ‘Long way to go’ before top pharma companies’ digital presence measures up to current tech standards: study

Νέα θεραπεία αναστέλλει την εξέλιξη της βλάβης στην ψωριασική αρθρίτιδα

  Έγκριση στη συμπερίληψη νέων στοιχείων έδωσε ο Οργανισμός Τροφίμων και Φαρμάκων των Η.Π.Α. (FDA) στη σεκουκινουμάμπη, βάσει των οποίων επιτυγχάνεται σημαντική επιβράδυνση στην εξέλιξη της δομικής βλάβης των αρθρώσεων την … Continue Reading Νέα θεραπεία αναστέλλει την εξέλιξη της βλάβης στην ψωριασική αρθρίτιδα

Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that … Continue Reading Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Novartis Spinout resTORbio Hits Endpoints on Phase II Trial of Respiratory Infections

  Boston-based resTORbio, which was spun out of Novartis in April 2017, announced positive topline results from its Phase IIb clinical trial of RTB101 in patients with respiratory tract infections (RTIs). RTB101 is an oral, selective, and potent … Continue Reading Novartis Spinout resTORbio Hits Endpoints on Phase II Trial of Respiratory Infections